A comparative study of the efficacy and toxicity of etodolac and naproxen in the treatment of osteoarthritis.
In a two-period, double-blind, crossover study, patients with osteoarthritis of the knee and/or hip received etodolac 300 mg twice daily for 4 weeks and naproxen 500 mg twice daily for 4 weeks in random order. The assessment of efficacy showed that naproxen and etodolac were equally effective in the management of pain and stiffness in osteoarthritis. However, a significantly higher proportion of patients preferred naproxen to etodolac for the relief of pain intensity. The incidence of adverse events caused by either drug was the same.
Department of Rheumatology, United Medical School, Guy's Hospital, London.
I C
IC
Chikanza
B
B
Clarke
R
R
Hopkins
D G
DG
MacFarlane
H
H
Bird
R
R
Grahame
D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D017308:Etodolac / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007719:Knee Joint; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*; D015207:Osteoarthritis, Hip / Q000188:drug therapy; D016896:Treatment Outcome
D017308:Etodolac; D009288:Naproxen